EUVIMEDEUVIMED entdecken
Multizentrische Studie

Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study

Takahiro Inoue, Michihisa Kono, Takumi Kumai iD, Kazufumi Obata, Satoshi Kano, Akira Ohkoshi, Akito Kakiuchi, Jun Taguchi, Ai Tagawa, Daisuke Matsushita, Jun Miyaguchi, Tentaro Endo und 8 weitere

Cancer · 15.04.2026 · 132 (8)

DOI: 10.1002/cncr.70429 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 21.04.2026. Verfasst von Takahiro Inoue und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It remains unknown whether the treatment response to immune checkpoint inhibitors (ICIs) or cetuximab‐based chemotherapy (the EXTREME regimen) reflects the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). A retrospective multicenter study was conducted to elucidate the relationship between objective treatment response and survival in patients with R/M HNSCC.

Methods

Thirteen university hospitals and cancer centers participated in this study. The clinical course of patients with R/M HNSCC treated with ICIs or the EXTREME regimen as first‐line treatment was retrospectively investigated. The outcomes of interest were progression‐free survival (PFS) and overall survival (OS). In addition to objective responses, adverse events were evaluated for each treatment.

Results

In total, 751 patients with R/M HNSCC were included in this retrospective study. The best response to first‐line treatment was significantly associated with improved prognosis only in ICI‐based therapy, not in cetuximab‐based targeted therapy. ICI responders had longer PFS and OS than EXTREME responders. The median PFS was 22.9 months and the median OS was not reached in ICI responders, whereas the median PFS and OS in EXTREME responders were 5.0 and 16.9 months, respectively. In contrast, EXTREME nonresponders had longer OS than ICI nonresponders. The median OS was 11.9 and 13.0 months in ICI and EXTREME nonresponders, respectively. Immune‐related adverse events were also associated with prognosis in patients treated with ICIs.

Conclusions

This study highlights the prognostic significance of achieving an objective response with first‐line ICI‐based, not cetuximab‐based, treatment in R/M HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCetuximabMolecular Targeted TherapyNeoplasm MetastasisPrognosisProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

adverse eventscetuximab‐based chemotherapy (the EXTREME regimen)immune checkpoint inhibitorobjective response raterecurrent or metastatic head and neck squamous cell carcinoma

Substanzen

CetuximabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Otolaryngology-Head & Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
  • Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Otolaryngology-Head & Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Otolaryngology-Head & Neck Surgery, Sapporo Medical University, Sapporo, Japan.
  • Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Japan.

ORCID-Profile: Takumi Kumai

Zitieren

APA

Inoue, T., Kono, M., Kumai, T., Obata, K., Kano, S., Ohkoshi, A., Kakiuchi, A., Taguchi, J., Tagawa, A., Matsushita, D., Miyaguchi, J., Endo, T., Ishii, R., Ito, K., Ishida, E., Suzuki, T., Araki, N., Kawase, T., Takano, K., & Takahara, M. (2026). Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study. Cancer, 132(8). https://doi.org/10.1002/cncr.70429

Vancouver

Inoue T, Kono M, Kumai T, Obata K, Kano S, Ohkoshi A, et al. Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study. Cancer. 2026;132(8). doi:10.1002/cncr.70429

BibTeX
@article{Inoue2026,
  author = {Inoue, Takahiro and Kono, Michihisa and Kumai, Takumi and Obata, Kazufumi and Kano, Satoshi and Ohkoshi, Akira and Kakiuchi, Akito and Taguchi, Jun and Tagawa, Ai and Matsushita, Daisuke and Miyaguchi, Jun and Endo, Tentaro and Ishii, Ryo and Ito, Kazue and Ishida, Eiichi and Suzuki, Takahiro and Araki, Naoto and Kawase, Tomoki and Takano, Kenichi and Takahara, Miki},
  title = {Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {8},
  doi = {10.1002/cncr.70429}
}
Kostenlos starten →